Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026)
Viatris (VTRS) recorded quarterly Liabilities and Shareholders Equity of $36.8 billion in Q1 2026, down 0.96% quarter-over-quarter from $37.2 billion in Q4 2025, and down 4.26% on a YoY basis from $38.5 billion in Q1 2025.
Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Viatris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $36.8 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 4.26% year-over-year to $36.8 billion; the TTM figure through Mar 2026 stood at $150.4 billion (down 11.58% YoY), while the FY2025 annual figure was $37.2 billion, down 10.38% from the prior year.
- Liabilities and Shareholders Equity was $36.8 billion for Q1 2026 at Viatris, down from $37.2 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $53.5 billion in Q1 2022 to a low of $36.8 billion in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $45.0 billion across 5 years, with a median of $47.3 billion in 2024.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity grew 0.16% in 2023, then slipped 18.73% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $50.0 billion in 2022, then decreased by 4.67% to $47.7 billion in 2023, then decreased by 12.97% to $41.5 billion in 2024, then slipped by 10.38% to $37.2 billion in 2025, then slipped by 0.96% to $36.8 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $36.8 billion (Q1 2026), $37.2 billion (Q4 2025), and $37.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Viatris | - | - | 1.16 Bn | 36.83 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.83 Bn |
| Dec 31, 2025 | 37.19 Bn |
| Sep 30, 2025 | 37.92 Bn |
| Jun 30, 2025 | 38.41 Bn |
| Mar 31, 2025 | 38.47 Bn |
| Dec 31, 2024 | 41.50 Bn |
| Sep 30, 2024 | 44.75 Bn |
| Jun 30, 2024 | 45.33 Bn |
| Mar 31, 2024 | 47.34 Bn |
| Dec 31, 2023 | 47.69 Bn |
| Sep 30, 2023 | 48.74 Bn |
| Jun 30, 2023 | 48.70 Bn |
| Mar 31, 2023 | 49.29 Bn |
| Dec 31, 2022 | 50.02 Bn |
| Sep 30, 2022 | 48.66 Bn |
| Jun 30, 2022 | 51.13 Bn |
| Mar 31, 2022 | 53.47 Bn |
| Dec 31, 2021 | 54.84 Bn |
| Sep 30, 2021 | 56.07 Bn |
| Jun 30, 2021 | 57.98 Bn |